The raised guidance and VITAS's accelerating growth trajectory (ADC +6.1%, revenue +11.9%) with minimal Medicare Cap headwinds are the key catalysts. Traders should watch for continued share repurchases (10.5% share reduction over trailing 12 months) and monitor the July 29 conference call for further operational detail. The 17.8% YoY adjusted EPS growth implied by guidance midpoint supports further upside.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 29 $539.36entry
- T+1 · 4mo ago −0.85%α −2.52% · $534.79
- T+5 · 3mo ago +1.33%α −4.20% · $546.51
- T+20 · 3mo ago +1.71%α −3.31% · $548.56
- T+60 · 26d ago −3.56%α −8.29% · $520.15
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Chemed reported Q2 2026 GAAP EPS of $5.13 (up 43.7% YoY) and revenue of $673.3M (up 8.8% YoY), beating consensus estimates of $5.60 EPS and $665.0M revenue by 0.9% and 1.2%, respectively. The beat was driven by VITAS's strong performance, with revenue up 11.9% and a sharp reduction in Medicare Cap billing limitations ($0.5M vs $16.4M last year). Guidance was raised meaningfully, with full-year adjusted EPS now $25.00-$25.75 (up from $24.00-$24.75), and VITAS ADC/revenue growth and EBITDA margin targets all revised upward, making this a clear bullish catalyst.
Key Financial Metrics
Key Facts
- Revenue $673.3M (+8.8% YoY) vs consensus $665.0M
- GAAP diluted EPS $5.13 (+43.7% YoY) vs consensus $5.60
- Adjusted diluted EPS $6.06 (+41.9% YoY)
- VITAS net revenue $443.3M (+11.9% YoY), ADC up 6.1% to 23,687
- Medicare Cap billing limitation dropped to $0.5M from $16.4M in Q2 2025
- Roto-Rooter revenue $229.9M (+3.3% YoY), EBITDA essentially flat
- Full-year adjusted EPS guidance raised to $25.00-$25.75 from $24.00-$24.75
- VITAS guidance raised: ADC growth 5.75%-6.25%, revenue growth ex-Medicare Cap 8.25%-9.25%, EBITDA margin 19.0%-19.5%
- Company repurchased 210,000 shares for $89.8M in Q2, $139.8M remaining authorization
- Cash $40.2M, long-term debt $140.0M, new $450M credit facility
Financial Impact
Revenue beat consensus by $8.3M (+1.2%); GAAP EPS beat consensus by $0.53 (+9.5%); adjusted EPS guidance midpoint raised by $1.00 (+4.1%)
Risk Factors
- Medicare Cap billing limitation of $7.0M still expected for full year 2026 across four provider numbers
- Roto-Rooter EBITDA margin declining 77 bps to 21.1% and revenue growth slowing to 3.3%
- High-acuity days-of-care declining 24 bps to 2.2% of total days, pressuring revenue per patient day
- Significant share repurchase activity ($287.5M YTD) reduces float but also depletes cash reserves
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3334743 |
Track record
19 reports on CHE
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 6, 202610d ago Press Release Neutral 2/10 Entry $528.05 to $548.20 Now $549.45 +4.05% ▲ +3.82% +1.22% vs SPY
- Nov 5, 202611d ago Insider Cluster Bearish 4/10 Entry $533.77 to $550.20 Now $549.45 −2.94% ▼ −3.08% +0.21% vs SPY
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $533.65 to $544.49 Now $549.45 +2.96% ▲ +2.03% +2.62% vs SPY
- Oct 27, 202620d ago Institutional Cluster Mixed 4/10 Entry $533.36 to $548.64 Now $549.45 +3.02% ▲ +2.86% +3.58% vs SPY
- Oct 27, 202620d ago 8-K Bullish 6/10 No price data
- Oct 27, 202620d ago Press Release Bullish 6/10 Entry $533.36 to $548.64 Now $549.45 +3.02% ▲ +2.86% +3.58% vs SPY
- Oct 23, 202624d ago Institutional Cluster Mixed 3/10 Entry $512.98 to $534.72 Now $549.45 +7.11% ▲ +4.24% +4.80% vs SPY
- Oct 1, 20266w ago Press Release Neutral 1/10 Entry $502.90 to $498.25 Now $549.45 +9.26% ▼ −0.92% −2.23% vs SPY
- Sep 16, 20268w ago Press Release Neutral 4/10 Entry $505.97 to $495.65 Now $549.45 +8.59% ▼ −2.04% −2.64% vs SPY
- Aug 24, 202612w ago Insider Cluster Neutral 3/10 Entry $541.34 to $518.71 Now $549.45 +1.50% ▼ −4.18% −4.65% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers